Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/0003-4819-154-3-201102010-00011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of systemic immune-inflammation index (SII) with risk of psoriasis: a cross-sectional analysis of National Health and Nutrition Examination Survey 2011-2014.
Eur J Med Res
January 2025
The Department of Pediatrics, The Third Xiangya Hospital of Central South University, Changsha, 410013, Hunan, China.
Background: The systemic immune-inflammation index (SII) is an emerging marker of inflammation, and the onset of psoriasis is associated with inflammation. The aim of our study was to investigate the potential impact of SII on the incidence rate of adult psoriasis.
Methods: We conducted a cross-sectional study based on the National Health and Nutrition Examination Survey (NHANES) 2011-2014 data sets.
Predictors of cytomegalovirus infection in patients with connective tissue disease treated by pulsed methylprednisolone therapy: a multicenter retrospective cohort study.
BMC Infect Dis
January 2025
Department of Dermatology, Showa University School of Medicine, 1-5-8, Hatanodai, Shinagawa-ku, Tokyo, 142-8555, Japan.
Article Synopsis
- This study investigates predictors of cytomegalovirus (CMV) infection in immunosuppressed patients with connective tissue disease undergoing pulsed-methylprednisolone (p-MPSL) therapy.
- It is a retrospective cohort study that analyzed 200 patients' data, identifying key baseline characteristics linked to increased risk of CMV infection, including age, platelet count, lymphocyte count, and specific blood ratio metrics.
- The findings highlight that older age and low blood cell counts significantly elevate the likelihood of CMV antigen positivity, providing insights for risk assessment in similar patient populations.
The Potential Clinical Relevance of Procoagulant Microparticles as Biomarkers of Blood Coagulation in Breast Cancer: A Systematic Review.
Asian Pac J Cancer Prev
January 2025
Research Center for Noncommunicable Disease, Jahrom University of Medical Sciences, Jahrom, Iran.
Background: Breast cancer (BC) is a global challenge that affects a large portion of individuals, especially women. It has been suggested that microparticles (MPs) can be used as a diagnostic, prognostic, or therapeutic biomarker in various diseases. Moreover, MPs are known to elevate in cancer cases.
View Article and Find Full Text PDFReal‑world therapeutic strategies and survival outcomes in advanced HER2-mutant non-small cell lung cancer.
J Chin Med Assoc
January 2025
Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ROC.
Background: Limited information is available regarding the clinical features and outcomes of advanced human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) in Taiwan, despite expanding treatment options for this distinct subtype. The present study explored the clinical features and outcomes of HER2-mutant NSCLC in a real-world setting.
Methods: Relevant data were collected from patients with advanced or recurrent HER2-mutant NSCLC who received systemic therapy between 2011 and 2021 and were followed up until 2022 at two medical centers in Taiwan.
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL.
Nat Commun
January 2025
Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Chronic lymphocytic leukemia is a malignant lymphoproliferative disorder for which primary or acquired drug resistance represents a major challenge. To investigate the underlying molecular mechanisms, we generate a mouse model of ibrutinib resistance, in which, after initial treatment response, relapse under therapy occurrs with an aggressive outgrowth of malignant cells, resembling observations in patients. A comparative analysis of exome, transcriptome and proteome of sorted leukemic murine cells during treatment and after relapse suggests alterations in the proteasome activity as a driver of ibrutinib resistance.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!